Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576951 · ClinicalTrials.gov registry record · Phase 1
A Study of Galcanezumab in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 178
- Enrollment target
NCT02576951: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02576951 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 178 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (197% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576951, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 178 participants
- Enrollment target
Study Summary
The purposes of this study are: * To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A) * To measure how much of the Galcanezumab lyophilized (freeze dried) injectable formulation is absorbed into the blood stream and how long it takes the body to get rid of it compared to the Galcanezumab solution injectable formulation after a single injection under the skin (subcutaneous \[SC\]) (Part B). Information about any side effects that may occur will also be collected. Each part of the study will last about six months. Participants may only enroll in one part.
Primary Outcome
If an injection site reaction is present, it will be fully characterized (including erythema, induration, pain, itching). A summary of other nonserious adverse event (AE), and all serious adverse events (SAE), regardless of causality, is located in the reported adverse events section.
Interventions
- DRUG Placebo
- DRUG Galcanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2015-10-19 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 1 |
What the finished NCT02576951 record still lists
NCT02576951 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (197% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02576951 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02576951 about?
NCT02576951 is a clinical study titled "A Study of Galcanezumab in Healthy Participants". The purposes of this study are: * To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A) * To measure how much of the Galcanezumab lyophilized (freeze dried) injectable formulation is absorbed into the blood stream and how long it takes the body to get rid of it compa...
What is the current status of trial NCT02576951?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2015-10-19. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02576951?
The interventions under investigation include: Placebo (DRUG), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT02576951?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02576951's enrollment target sits among peer trials
178 311th of 2000 higher than 1,688 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI